The aim of this placebo-controlled study was to determine whether once-weekly @entity19160 could prevent @entity170 in @entity1 with @entity625 at the start of corticosteroid therapy. One hundred sixty-three @entity1 , 18 to 90 years of age, with @entity309 or @entity5144 , were randomly assigned to receive either @entity19160 (100 mg im/week) plus @entity460 and @entity560 (1000 mg and 800 UI, respectively) or @entity460 and @entity560 alone. @entity1 had started therapy with @entity229 or its equivalent within the previous 100 days and had bone mineral density <2.5 SD below mean young normal values at the lumbar spine or femoral neck. The primary outcome was the difference between the two treatment groups at months 12, 24, 36, and 48 in the mean percentage change from baseline in the bone mineral density of the lumbar spine, femur (neck and total), and total body. Secondary measurements included changes in the stiffness index evaluated by ultrasound measurements and the rate of new @entity174 . The bone density and stiffness did not change significantly in the @entity19160 plus @entity460 and @entity560 group, whereas it declined significantly in the @entity460 plus @entity560 group. The difference between treatment groups at 48 months in the mean change from baseline was 8.78 +/- 1.4% for the lumbar spine (P < 0.01), 7.31 +/- 1.12% for the femoral neck (P < 0.01), 7.92 +/- 1.93% for the trochanter (P < 0.01), 8.39 +/- 1.80% for total femur (P < 0.01), 6.94 +/- 1.09% for total body (P < 0.01), and 9.38 +/- 2.21% for stiffness of os calcis (P < 0.01). Depending on the skeletal regions evaluated, 85 to 98% of @entity1 treated with @entity19160 had a densitometric change lower than the lowest significant densitometric difference. One hundred percent of @entity1 treated with @entity460 plus @entity560 had a densitometric decrease greater than the lowest significant difference. The relative risk of @entity174 and @entity174 in the @entity19160 group compared to the @entity460 plus @entity560 group was 0.63 (0.35-0.98, 95% CI) and 0.25 (0.15-0.91, 95% CI), respectively. We concluded that pulsatory administration of im @entity19160 once weekly is a safe therapy for preventing corticosteroid induced @entity170 in @entity1 with @entity625 .

Effects of 4-year treatment with once-weekly @entity19160 on prevention of corticosteroid-induced bone loss and XXXX in @entity1 with @entity625 : evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity174 :: ('MESH:D050723', 'Disease') :: ['multiple vertebral fractures', 'vertebral fractures'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic arthritis'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity19160 :: ('MESH:D004002', 'Chemical') :: ['clodronate'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity174 :: (MESH:D050723,Disease) :: ['fractures']
